Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis.

Brian Chan¹, Ryan Cook², Ximena Levander², Katharina Wiest³, Kim Hoffman², Kellie Pertl³, Ritwika Petluri³, Dennis McCarty⁴, P Todd Korthuis⁵, Stephen A Martin⁶

¹Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America; Central City Concern, Portland, OR, United States of America. Electronic address: chanbri@ohsu.edu.

²Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America.

³Boulder Care, Portland, OR, United States of America.

⁴School of Public Health, Oregon Health & Science University and Portland State University, Portland, OR, United States of America.

⁵Division of General Internal Medicine and Geriatrics, Section of Addiction Medicine, Oregon Health & Science University, Portland, OR, United States of America; School of Public Health, Oregon Health & Science University and Portland State University, Portland, OR, United States of America.

⁶Boulder Care, Portland, OR, United States of America; Department of Family Medicine and Community Health, UMass Chan Medical School, Worcester, MA, United States of America.

PubMed PMC DOI PDF

Abstract

INTRODUCTION: At the beginning of the COVID-19 pandemic, federal agencies permitted telehealth initiation of buprenorphine treatment for opioid use disorder (OUD) without in-person assessment. It remains unclear how telehealth-only buprenorphine treatment impacts time to discontinuation and patient reported treatment outcomes. METHODS: A longitudinal observational cohort study conducted September…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Mentioned Companies

Boulder Care
affiliation

NIH Funding

Grant #11122242
Transporting treatment effects from clinical trials to real-world populations with co-occurring opioid and stimulant use disorders
OREGON HEALTH & SCIENCE UNIVERSITY
$200,657 (FY2025)
Grant #10380909
Evaluating the Usability, Efficacy and Commercial Utility of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder
BOULDER CARE, INC.
$673,318 (FY2022)

Other Funding

NIDA NIH HHS(K01 DA055130)
United States
NIDA NIH HHS(UG1 DA015815)
United States
NIDA NIH HHS(R44 DA050354)
United States
AHRQ HHS(K12 HS026370)
United States
NIDA NIH HHS(K23 DA053390)
United States

MeSH Terms

Humans0Buprenorphine*Female0Opioid-Related Disorders*Male0Adult0Longitudinal Studies0Telemedicine*Opiate Substitution Treatment*Middle Aged0COVID-190Oregon0Washington0Cohort Studies0

Keywords

Medications for opioid use disorderOpioid use disorderTelemedicine

Article Info

PMID: 39243979
PMCID: PMC12002408
DOI: 10.1016/j.josat.2024.209511
Received: March 15, 2024
Accepted: August 27, 2024

How to Cite

Chan B et al. Buprenorphine discontinuation in telehealth-only treatment for opioid use disorder: A longitudinal cohort analysis. J Subst Use Addict Treat2024;167209511. doi:10.1016/j.josat.2024.209511

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.